New Label Claim Extends Use of Swine Antibiotic

CANADA - Draxxin® is now registered for control of swine respiratory disease (SRD) in groups of pigs where SRD has been diagnosed.
calendar icon 18 October 2010
clock icon 3 minute read

This additional claim provides Canadian veterinarians with more confidence and flexibility when using Draxxin to control disease in animals that have been in contact with pigs affected by SRD.

Draxxin (tulathromycin) is the first and only injectable antibiotic with a control claim for use in pigs assessed to be at risk of developing SRD because of their proximity to sick animals. With the additional label claim, Draxxin is indicated for the treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida and Mycoplasma hyopneumoniae and for the control of SRD caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

“This new claim provides Canadian veterinarians with an approved option for the use of Draxxin to control SRD in pigs where disease is expected,“ says Don McDermid, DVM, Veterinary Operations for Pfizer Animal Health. “And controlling disease early, often before clinical symptoms appear, can be in the best interest of the animal as early treatment leads to better responses.“

Additionally, veterinarians can feel confident using Draxxin as a review by the Veterinary Medicine Advisory Council found that label use of Draxxin poses no appreciable risk to public health with respect to microbial food safety.

Draxxin provides full therapy with one injection and has a long duration of activity with an eight-day withdrawal period in swine. Draxxin is available exclusively through veterinarians. Consult your herd veterinarian on how Draxxin may fit your herd health protocol.

© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.